The authors then investigated the demethylation machinery in ITGCNU cells and showed that they closely parallel PCGs and maintain their genome in a demethylated and undifferentiated state, even in the presence of de novo methyltransferases. Acquisition of further somatic mutations, that is, in the stem cell factor receptor c-KIT (CD117) or other oncogenic drivers then steer expanding germ cells after puberty into further progression of TGCC (Tian et al, 1999; Biermann et al, 2007) .
Where will we go from here and will the understanding of basic principles of tumourigenesis translate into better treatment of patients? It is obvious that the development of targeted cancer therapies resulted from profound understanding of oncogenic driver mutations and from subsequent application of selective inhibitors such as the tyrosine kinase inhibitor Imatinib targeting the genomically modified abl-kinase or gain-of-function mutations in c-KIT. Likewise, it will be rewarding to develop specific and selective inhibitors for epigenetic enzymes or their pathways and to determine the window of application in tumours that rely on their pathologically altered activity. Thus, there is no single breakthrough in oncology but rather many individual steps of developing personalised and selective cancer medicines.
